Buy It or Sell It? Cyclerion Therapeutics (NASDAQ:CYCN) Releases CY6463 Preclinical Data

Cyclerion Therapeutics (NASDAQ:CYCN) is moving higher in the opening session after the news on Friday

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

  • announced the publication of preclinical data of CY6463 in Frontiers in Pharmacology. Cyclerion is developing CY6463, an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator, for neurological diseases associated with cognitive impairment, including Alzheimer’s disease with vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), as well as Cognitive Impairment Associated with Schizophrenia (CIAS).
  • Cyclerion identified and developed CY6463 based on its ability to readily access the CNS and amplify nitric oxide‐soluble guanylate cyclase‐cyclic guanosine monophosphate (NO-sGC-cGMP) signaling in the brain. CY6463 was designed to address multiple pathophysiological features of neurodegenerative and neuropsychiatric diseases associated with cognitive impairment.
  • Extensive preclinical data from CY6463 and decades of research validate the crucial role of the sGC pathway in brain physiology and cognition. Across a range of preclinical models, administration of CY6463 resulted in physiologically relevant drug levels in cerebrospinal fluid (CSF) and led to improvements in neuronal function, neuroprotection, and cognitive performance. Together, these data further support the clinical development of CY6463 as a novel and potentially paradigm-shifting approach to the treatment of neurodegenerative and neuropsychiatric disorders.

Market Action

As of 9:41, CYCN stock jumped $0.05 or 3.25% to $2.20. So far the stock has traded 72K shares. After opening at $3.25, the stock has moved within a range of 3.2000 – 3.3300.

Related Posts

About The Author